Therapy for unresectable recurrent and in-transit extremity melanoma (Q33348506)

26 July 2017

1 reference

title

Therapy for unresectable recurrent and in-transit extremity melanoma (English)

1 reference

26 July 2017

Mark I Gimbel

1

1 reference

26 July 2017

Keith A Delman

series ordinal

2

1 reference

26 July 2017

Jonathan S Zager

series ordinal

3

1 reference

26 July 2017

1 July 2008

1 reference

26 July 2017

1 reference

26 July 2017

15

1 reference

26 July 2017

3

1 reference

26 July 2017

225-232

1 reference

An evidence-based staging system for cutaneous melanoma

26 July 2017

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

Fraction size in external beam radiation therapy in the treatment of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

Some factors of importance in the radiation treatment of malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

Use of the carbon dioxide laser to manage cutaneous metastases from malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

Ten-year experience of carbon dioxide laser ablation as treatment for cutaneous recurrence of malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Easter

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

Complete remission of cutaneous satellite and in-transit metastases. After intralesional therapy with interleukin-2 in 2 patients with malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

Electrochemotherapy: aspects of preclinical development and early clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

Vascular reactions to in vivo electroporation: characterization and consequences for drug and gene delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

Transient electropermeabilization of cells in culture. Increase of the cytotoxicity of anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

Electrochemotherapy in treatment of tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

Electrochemotherapy a novel approach to the treatment of metastatic nodules on the skin and subcutaneous tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

Electrochemotherapy – An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrod

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

Spatial and temporal control of gene therapy using ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

Local gene delivery of tumor necrosis factor alpha can impact primary tumor growth and metastases through a host-mediated response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

Temozolomide for the treatment of metastatic melanoma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

Management of in-transit melanoma of the extremity with isolated limb perfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

Hyperthermic regional perfusion for melanoma and sarcoma of the limbs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

Thirty-five years of isolated limb perfusion for melanoma: indications and results

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

Isolated limb perfusion with melphalan in the treatment of malignant melanoma of the extremities: a systematic review of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

Long-term locoregional vascular morbidity after isolated limb perfusion and external-beam radiotherapy for soft tissue sarcoma of the extremity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480801500305

10.1177/107327480801500305

21 January 2018

Identifiers

DOI

0 references

1 reference